Research Councils UK

argenx Highlights 2024 Strategic Priorities

Retrieved on: 
Lundi, janvier 8, 2024
Immunoglobulin therapy, GMG, FDA, PRV, Congenital myasthenic syndrome, ARDA, Research Councils UK, Euronext, Inflammation, Cohort, PGIC, NRDL, Autoimmunity, Efgartigimod alfa, Dermatomyositis, Conference, MuSK protein, IND, CIDP, Pharmacokinetics, MMN, Safety, Therapy, Patient, ALS, Immune system, IL-6, Medicine, International Myeloma Foundation, IIP, FSS, Neonatal Fc receptor, Multifocal motor neuropathy, Growth, Pharmaceutical industry

argenx is planning to reach more patients commercially in 2024 through its multi-dimensional expansion efforts.

Key Points: 
  • argenx is planning to reach more patients commercially in 2024 through its multi-dimensional expansion efforts.
  • In addition, ARGX-119, a muscle-specific kinase (MuSK) agonist, will initiate Phase 1b/2a studies in congenital myasthenic syndrome and amyotrophic lateral sclerosis in 2024.
  • As of December 31, 2023, argenx had approximately $3.2 billion in cash, cash equivalents and current financial assets*.
  • Based on its current operating plans, argenx expects its combined R&D and SG&A expenses in 2024 to be less than $2 billion.

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

Retrieved on: 
Mardi, juin 20, 2023
ARDA, Cohort, Immunoglobulin therapy, IDMC, Pharmacokinetics, Research Councils UK, Multifocal motor neuropathy, MMN, Euronext, International Myeloma Foundation, Patient, The Retreat, SE, Autoimmunity, Safety, Pharmaceutical industry, Vaccine, C2

“We are encouraged by the favorable safety profile and early efficacy signals from the ARDA study, as well as the IDMC recommendation to advance the study to the next cohort.

Key Points: 
  • “We are encouraged by the favorable safety profile and early efficacy signals from the ARDA study, as well as the IDMC recommendation to advance the study to the next cohort.
  • The IDMC confirmed a favorable safety and tolerability profile of empasiprubart consistent with results from the Phase 1 study and recommended advancing to the second cohort.
  • The study’s objective, in addition to assessing safety and efficacy of empasiprubart, is to populate a PK/PD model to inform the Phase 3 study dose selection.
  • The Phase 2 ARDA study is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of two dose regimens of empasiprubart in adults with multifocal motor neuropathy (MMN).

National Research Council of Science & Technology and Elsevier sign pilot agreement to support open access publishing alongside continued research access in South Korea

Retrieved on: 
Vendredi, décembre 18, 2020
Articles, Academic publishing, Publishing, Academia, Open science, Research Councils UK, Open access, NST

It also enables South Korean researchers to publish their research open access.

Key Points: 
  • It also enables South Korean researchers to publish their research open access.
  • In line with the global trend of Open Science and the sharing of research data, NST will endeavour to accelerate the transition to open access."
  • South Korea's National Research Council of Science & Technology (NST) is supporting 25 government-funded research institutes(GRI) in the science and technology fields to remain committed to their mission and objectives with their competitive and challenging spirit.
  • In South Korea, GRIs have been the driving force of economic growth as well as South Korea's science and technology development.

Better information, better decisions: Government of Canada launches new studies on mobility and public transit

Retrieved on: 
Lundi, septembre 14, 2020
Articles, Innovation, Science and Economic Development Canada, Social Sciences and Humanities Research Council, Government, Economy, Infrastructure, Public transport, Research Councils UK

Today,the Honourable Catherine McKenna, Minister of Infrastructure and Communities, andDr.TedHewitt, President of the Social Sciences and Humanities Research Council (SSHRC), announced funding for up to 10 Knowledge Synthesis Grants on mobility and public transit.

Key Points: 
  • Today,the Honourable Catherine McKenna, Minister of Infrastructure and Communities, andDr.TedHewitt, President of the Social Sciences and Humanities Research Council (SSHRC), announced funding for up to 10 Knowledge Synthesis Grants on mobility and public transit.
  • The projects will focus on consolidating and reviewing existing research findings, knowledge and data tobetter understand transit issues at the community level, leading to better, more strategic infrastructure investments.
  • "Public transit allows Canadians to get where they need to go quickly, cheaply and efficiently.
  • "The Social Sciences and Humanities Research Council is very pleased to partner with Infrastructure Canada on this special initiative.